广泛期小细胞肺癌化疗后胸部大分割放疗的近期疗效及毒性分析

Analysis of Short-term Efficacy and Toxicity of Large Thoracic Fractionation Radiotherapy after Chemotherapy in Patients with Extensive Small Cell Lung Cancer

目的探讨广泛期小细胞肺癌(ES-SCLC)化疗后行胸部大分割放疗的近期疗效及毒性反应。方法回顾性分析2014年1月至2016年12月北京市朝阳区桓兴肿瘤医院收治的26例初治ES-SCLC化疗后行胸部大分割放疗患者的临床资料,分析放射性肺炎、放射性食管炎的发生率,应用Kaplan-Meier检验比较ES-SCLC化疗后胸部大分割放疗对生存期的影响。结果26例化疗后行大分割放疗的ES-SCLC患者均顺利完成治疗,Ⅱ级放射性肺炎发生率为19.2%,无Ⅲ级以上放射性肺炎或Ⅲ级以上放射性食管炎发生。1年局部控制率和无进展生存率分别为69.2%、57.7%。结论ES-SCLC化疗后行胸部大分割放疗可提高患者的近期疗效,且未增加毒性反应。

Objective To investigate the short-term efficacy and toxicity of large thoracic fractionation radiotherapy after chemotherapy in patients with extensive small cell lung cancer(ES-SCLC).Methods A retrospective analysis was made with the clinical data of 26 patients with large-segment chest radiotherapy after initial ES-SCLC chemotherapy in Beijing Chaoyang District Huanxing Tumor Hospital from Jan.2014 to Dec.2016.The incidence of radiation pneumonia and esophagitis was analyzed.The effects of large-segment chest radiotherapy after ES-SCLC chemotherapy on survival period were compared by Kaplan-Meier test.Results All of the 26 ES-SCLC patients who received large fraction radiotherapy after chemotherapy successfully completed the treatment.The incidence of gradeⅡradiation pneumonia was 19.2%.No gradeⅢor above radiation pneumonia or gradeⅢradiation esophagitis occurred.One-year local control rate and progression-free survival rate were 69.2%and 57.7%respectively.Conclusion Large thoracic fractionation radiotherapy after ES-SCLC chemotherapy can improve the short-term efficacy without increasing toxicity.